211 related articles for article (PubMed ID: 30559064)
1. Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons.
Hamid AA; Morris MJ; Davis ID
Eur Urol Focus; 2019 Mar; 5(2):165-167. PubMed ID: 30559064
[TBL] [Abstract][Full Text] [Related]
2. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.
Yu EY; Gillessen S; Mottet N
Eur Urol Focus; 2019 Mar; 5(2):162-164. PubMed ID: 30287277
[TBL] [Abstract][Full Text] [Related]
3. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
[TBL] [Abstract][Full Text] [Related]
4. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
[TBL] [Abstract][Full Text] [Related]
5. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
Scott LJ
Drugs; 2017 Sep; 77(14):1565-1576. PubMed ID: 28819727
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
Akaza H; Procopio G; Pripatnanont C; Facchini G; Fava S; Wheatley D; Leung KC; Butt M; Silva A; Castillo L; Karavasilis V; Ӧzatılgan A; Hitier S; Ecstein-Fraisse EB; Ӧzgüroḡlu M
J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30260754
[TBL] [Abstract][Full Text] [Related]
9. [Review on quality of life in CRPC patients].
Miller K
Aktuelle Urol; 2017 May; 48(3):219-224. PubMed ID: 28614882
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Castration-naive Metastatic Prostate Cancer.
Hamilou Z; Baciarello G; Fizazi K
Eur Urol Focus; 2017 Dec; 3(6):518-521. PubMed ID: 29500136
[TBL] [Abstract][Full Text] [Related]
11. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hormone-naïve metastatic prostate cancer.
Hamilou Z; Saad F; Fizazi K
Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
[TBL] [Abstract][Full Text] [Related]
13. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
Grisay G; Lavaud P; Fizazi K
Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
Caffo O; Veccia A; Kinspergher S; Maines F
Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
[TBL] [Abstract][Full Text] [Related]
15. Long-term abiraterone withdrawal syndrome.
Marin S; Querol R; Campins L; Miarons M; Font A; Lianes P
J Clin Pharm Ther; 2018 Oct; 43(5):714-716. PubMed ID: 29722038
[TBL] [Abstract][Full Text] [Related]
16. Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
Vicier C; Feng FY; Fizazi K
Eur Urol Focus; 2019 Mar; 5(2):168-170. PubMed ID: 30745118
[TBL] [Abstract][Full Text] [Related]
17. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
18. Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
Geynisman DM; Ross EA; Plimack ER
Eur Urol; 2015 Oct; 68(4):578-80. PubMed ID: 26116295
[No Abstract] [Full Text] [Related]
19. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer-The Forgotten Dance Partner?
Klaassen Z; Wallis CJD; Fleshner NE
JAMA Oncol; 2019 Feb; 5(2):144-145. PubMed ID: 30489621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
